Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis

Virender Kumar, Vinod Kumar, Jiangtao Luo, Ram I Mahato

Research output: Contribution to journalArticle

Abstract

Trans-differentiation of quiescent hepatic stellate cells (HSCs) into active myofibroblasts secretes excess amounts of extracellular matrix (ECM) proteins. miR-29b1 has the potential to treat liver fibrosis, because it targets several profibrotic genes. We previously demonstrated that miR-29b1 and the hedgehog (Hh) pathway inhibitor GDC-0449 could, together, inhibit the activation of HSCs and ECM production in common bile-duct-ligated (CBDL) mice. Herein, we determined the effect of chemical modifications of miR-29b1 on its stability, immunogenicity, and Argonaute-2 (Ago2) loading in vitro, after modifying its antisense strand with phosphorothioate (PS-miR-29b1), 2′-O-methyl-phosphorothioate (OMe-miR-29b1), locked nucleic acid (LNA-miR-29b1), and N,N’-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine (ZEN-miR-29b1). Chemical modifications significantly improved stability of miR-29b1 in 50% FBS. Among all the modified miRNAs tested, OMe-PS-miR-29b1 showed the highest stability with low immunogenicity, without the loss of efficacy in vitro. Therefore, OMe-PS-miR-29b1 was complexed with poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylenecarbonate-graft-dodecanol-graft-tetraethylenepentamine (mPEG-b-PCC-g-DC-g-TEPA) cationic micelles, and anti-fibrotic efficacy was evaluated in CBDL mice. There was a significant improvement in liver histology and decrease in the levels of injury markers. Further, mRNA/protein levels of collagen, α-SMA, and TIMP-1 were significantly lower for the OMe-PS-miR-29b1-loaded micelles compared to miR-29b1-loaded micelles. In conclusion, micellar delivery of OMe-PS-miR-29b1 is a promising strategy to treat liver fibrosis. Kumar et al. demonstrated the improved serum stability, immunogenicity, and efficacy of miR-29b1 when modified with 2′-O-methyl-phosphorothioate. Systemic administration of OMe-PS-miR-29b1 micellar formulation significantly decreased the levels of liver injury markers, collagen, and proinflammatory cytokines. Therefore, this is a promising strategy for treating liver and other fibroses.

Original languageEnglish (US)
Pages (from-to)2798-2811
Number of pages14
JournalMolecular Therapy
Volume26
Issue number12
DOIs
StatePublished - Dec 5 2018

Fingerprint

Micelles
Liver Cirrhosis
Hepatic Stellate Cells
Common Bile Duct
HhAntag691
Aniline Compounds
Triethylenephosphoramide
Collagen
Dodecanol
Transplants
Tissue Inhibitor of Metalloproteinase-1
Myofibroblasts
Hedgehogs
Ethylene Glycol
Extracellular Matrix Proteins
Liver
Wounds and Injuries
MicroRNAs
Extracellular Matrix
Histology

Keywords

  • CBDL
  • backbone modifications
  • liver fibrosis
  • miR-29b1
  • micelles

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis. / Kumar, Virender; Kumar, Vinod; Luo, Jiangtao; Mahato, Ram I.

In: Molecular Therapy, Vol. 26, No. 12, 05.12.2018, p. 2798-2811.

Research output: Contribution to journalArticle

Kumar, Virender ; Kumar, Vinod ; Luo, Jiangtao ; Mahato, Ram I. / Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis. In: Molecular Therapy. 2018 ; Vol. 26, No. 12. pp. 2798-2811.
@article{c3b7f4519d634bada50e2324c961a242,
title = "Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis",
abstract = "Trans-differentiation of quiescent hepatic stellate cells (HSCs) into active myofibroblasts secretes excess amounts of extracellular matrix (ECM) proteins. miR-29b1 has the potential to treat liver fibrosis, because it targets several profibrotic genes. We previously demonstrated that miR-29b1 and the hedgehog (Hh) pathway inhibitor GDC-0449 could, together, inhibit the activation of HSCs and ECM production in common bile-duct-ligated (CBDL) mice. Herein, we determined the effect of chemical modifications of miR-29b1 on its stability, immunogenicity, and Argonaute-2 (Ago2) loading in vitro, after modifying its antisense strand with phosphorothioate (PS-miR-29b1), 2′-O-methyl-phosphorothioate (OMe-miR-29b1), locked nucleic acid (LNA-miR-29b1), and N,N’-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine (ZEN-miR-29b1). Chemical modifications significantly improved stability of miR-29b1 in 50{\%} FBS. Among all the modified miRNAs tested, OMe-PS-miR-29b1 showed the highest stability with low immunogenicity, without the loss of efficacy in vitro. Therefore, OMe-PS-miR-29b1 was complexed with poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylenecarbonate-graft-dodecanol-graft-tetraethylenepentamine (mPEG-b-PCC-g-DC-g-TEPA) cationic micelles, and anti-fibrotic efficacy was evaluated in CBDL mice. There was a significant improvement in liver histology and decrease in the levels of injury markers. Further, mRNA/protein levels of collagen, α-SMA, and TIMP-1 were significantly lower for the OMe-PS-miR-29b1-loaded micelles compared to miR-29b1-loaded micelles. In conclusion, micellar delivery of OMe-PS-miR-29b1 is a promising strategy to treat liver fibrosis. Kumar et al. demonstrated the improved serum stability, immunogenicity, and efficacy of miR-29b1 when modified with 2′-O-methyl-phosphorothioate. Systemic administration of OMe-PS-miR-29b1 micellar formulation significantly decreased the levels of liver injury markers, collagen, and proinflammatory cytokines. Therefore, this is a promising strategy for treating liver and other fibroses.",
keywords = "CBDL, backbone modifications, liver fibrosis, miR-29b1, micelles",
author = "Virender Kumar and Vinod Kumar and Jiangtao Luo and Mahato, {Ram I}",
year = "2018",
month = "12",
day = "5",
doi = "10.1016/j.ymthe.2018.08.022",
language = "English (US)",
volume = "26",
pages = "2798--2811",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis

AU - Kumar, Virender

AU - Kumar, Vinod

AU - Luo, Jiangtao

AU - Mahato, Ram I

PY - 2018/12/5

Y1 - 2018/12/5

N2 - Trans-differentiation of quiescent hepatic stellate cells (HSCs) into active myofibroblasts secretes excess amounts of extracellular matrix (ECM) proteins. miR-29b1 has the potential to treat liver fibrosis, because it targets several profibrotic genes. We previously demonstrated that miR-29b1 and the hedgehog (Hh) pathway inhibitor GDC-0449 could, together, inhibit the activation of HSCs and ECM production in common bile-duct-ligated (CBDL) mice. Herein, we determined the effect of chemical modifications of miR-29b1 on its stability, immunogenicity, and Argonaute-2 (Ago2) loading in vitro, after modifying its antisense strand with phosphorothioate (PS-miR-29b1), 2′-O-methyl-phosphorothioate (OMe-miR-29b1), locked nucleic acid (LNA-miR-29b1), and N,N’-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine (ZEN-miR-29b1). Chemical modifications significantly improved stability of miR-29b1 in 50% FBS. Among all the modified miRNAs tested, OMe-PS-miR-29b1 showed the highest stability with low immunogenicity, without the loss of efficacy in vitro. Therefore, OMe-PS-miR-29b1 was complexed with poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylenecarbonate-graft-dodecanol-graft-tetraethylenepentamine (mPEG-b-PCC-g-DC-g-TEPA) cationic micelles, and anti-fibrotic efficacy was evaluated in CBDL mice. There was a significant improvement in liver histology and decrease in the levels of injury markers. Further, mRNA/protein levels of collagen, α-SMA, and TIMP-1 were significantly lower for the OMe-PS-miR-29b1-loaded micelles compared to miR-29b1-loaded micelles. In conclusion, micellar delivery of OMe-PS-miR-29b1 is a promising strategy to treat liver fibrosis. Kumar et al. demonstrated the improved serum stability, immunogenicity, and efficacy of miR-29b1 when modified with 2′-O-methyl-phosphorothioate. Systemic administration of OMe-PS-miR-29b1 micellar formulation significantly decreased the levels of liver injury markers, collagen, and proinflammatory cytokines. Therefore, this is a promising strategy for treating liver and other fibroses.

AB - Trans-differentiation of quiescent hepatic stellate cells (HSCs) into active myofibroblasts secretes excess amounts of extracellular matrix (ECM) proteins. miR-29b1 has the potential to treat liver fibrosis, because it targets several profibrotic genes. We previously demonstrated that miR-29b1 and the hedgehog (Hh) pathway inhibitor GDC-0449 could, together, inhibit the activation of HSCs and ECM production in common bile-duct-ligated (CBDL) mice. Herein, we determined the effect of chemical modifications of miR-29b1 on its stability, immunogenicity, and Argonaute-2 (Ago2) loading in vitro, after modifying its antisense strand with phosphorothioate (PS-miR-29b1), 2′-O-methyl-phosphorothioate (OMe-miR-29b1), locked nucleic acid (LNA-miR-29b1), and N,N’-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine (ZEN-miR-29b1). Chemical modifications significantly improved stability of miR-29b1 in 50% FBS. Among all the modified miRNAs tested, OMe-PS-miR-29b1 showed the highest stability with low immunogenicity, without the loss of efficacy in vitro. Therefore, OMe-PS-miR-29b1 was complexed with poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylenecarbonate-graft-dodecanol-graft-tetraethylenepentamine (mPEG-b-PCC-g-DC-g-TEPA) cationic micelles, and anti-fibrotic efficacy was evaluated in CBDL mice. There was a significant improvement in liver histology and decrease in the levels of injury markers. Further, mRNA/protein levels of collagen, α-SMA, and TIMP-1 were significantly lower for the OMe-PS-miR-29b1-loaded micelles compared to miR-29b1-loaded micelles. In conclusion, micellar delivery of OMe-PS-miR-29b1 is a promising strategy to treat liver fibrosis. Kumar et al. demonstrated the improved serum stability, immunogenicity, and efficacy of miR-29b1 when modified with 2′-O-methyl-phosphorothioate. Systemic administration of OMe-PS-miR-29b1 micellar formulation significantly decreased the levels of liver injury markers, collagen, and proinflammatory cytokines. Therefore, this is a promising strategy for treating liver and other fibroses.

KW - CBDL

KW - backbone modifications

KW - liver fibrosis

KW - miR-29b1

KW - micelles

UR - http://www.scopus.com/inward/record.url?scp=85054124042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054124042&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2018.08.022

DO - 10.1016/j.ymthe.2018.08.022

M3 - Article

C2 - 30287074

AN - SCOPUS:85054124042

VL - 26

SP - 2798

EP - 2811

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 12

ER -